Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 8, Number 7—July 2002
Research

Monitoring Antimicrobial Use and Resistance: Comparison with a National Benchmark on Reducing Vancomycin Use and Vancomycin-Resistant Enterococci

Scott K. Fridkin*, Rachel Lawton*, Jonathan R. Edwards*, Fred C. Tenover*, John E. McGowan†, Robert P. Gaynes*, and the Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project, and the National Nosocomial Infections Surveillance (NNIS) System Hospitals
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Emory University, Atlanta, Georgia, USA

Main Article

Figure 1

Boxplot of benchmark data of vancomycin use at all Phase 2 Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals (n=113 intensive-care units [ICUs]) in October 1997, by type of ICU (18). ICU types include pediatric (P), coronary (C), combined medical-surgical (MS), neurosurgical (NS), surgical (S), and cardiothoracic (CT). For each type of ICU, boxes represent rates of vancomycin use at the 25th–75th percentiles (interquartile range), and ends of vertical lines represent

Figure 1. . Boxplot of benchmark data of vancomycin use at all Phase 2 Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals (n=113 intensive-care units [ICUs]) in October 1997, by type of ICU (18). ICU types include pediatric (P), coronary (C), combined medical-surgical (MS), neurosurgical (NS), surgical (S), and cardiothoracic (CT). For each type of ICU, boxes represent rates of vancomycin use at the 25th–75th percentiles (interquartile range), and ends of vertical lines represent values at the 10th–90th percentiles. Horizontal lines represent median values in each ICU type. Additionally, plotted circles represent the rate of vancomycin use in the pre-intervention period (1996–1997) in the 50 ICUs participating in the intervention study, and open circles represent the 10 ICUs reporting a prescriber practice change identified in the specific unit (i.e., ICU-specific practice change) (1 burn ICU not shown). DDD, defined daily doses.

Main Article

References
  1. Jarvis  WR. Preventing the emergence of multidrug-resistant microorganisms through antimicrobial use controls: the complexity of the problem. Infect Control Hosp Epidemiol. 1996;17:490–5.PubMedGoogle Scholar
  2. Schwartz  B, Bell  D, Hughes  JM. Preventing the emergence of antimicrobial resistance: a call for action by clinicians, public health officials, and patients. JAMA. 1997;278:944–5. DOIPubMedGoogle Scholar
  3. Shlaes  DM, Gerding  DN, John  JF, Craig  WA, Bornstein  DL, Duncan  RA, Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol. 1997;18:275–91.PubMedGoogle Scholar
  4. Duncan  RA. Controlling use of antimicrobial agents. Infect Control Hosp Epidemiol. 1997;18:260–6.PubMedGoogle Scholar
  5. Gross  PA. The potential for clinical guidelines to impact appropriate antimicrobial agent use. Infect Dis Clin North Am. 1997;11:803–12. DOIGoogle Scholar
  6. Goldmann  DA, Weinstein  RA, Wenzel  RP, Tablan  OC, Duma  RJ, Gaynes  RP, Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. JAMA. 1996;275:234–40. DOIPubMedGoogle Scholar
  7. Hospital Infection control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol. 1996;16:105–13.
  8. Lawton  RM, Fridkin  SK, Gaynes  RP, McGowan  JE Jr. Practices to improve antimicrobial use at 47 U.S. hospitals: the status of the 1997 SHEA/IDSA position paper recommendations. Infect Control Hosp Epidemiol. 2000;21:256–9. DOIPubMedGoogle Scholar
  9. Burstin  HR, Conn  A, Setnik  G, Rucker  DW, Cleary  PD, O'Neil  AC, Benchmarking and quality improvement: the Harvard Emergency Department Quality Study. Am J Med. 1999;107:437–49. DOIPubMedGoogle Scholar
  10. O'Connor  GTP, Plume  SKM, Olmstead  EM, Morton  JRM, Maloney  CTM, Nugent  WCM, A regional intervention to improve the hospital mortality associated with coronary artery bypass graft surgery. JAMA. 1996;275:841–6. DOIPubMedGoogle Scholar
  11. Gulacsi  L, Kiss  ZT, Goldmann  DA, Huskins  WC. Risk-adjusted infection rates in surgery: a model for outcome measurement in hospitals developing new quality improvement programs. J Hosp Infect. 2000;44:43–52. DOIPubMedGoogle Scholar
  12. Centers for Disease Control and Prevention. Monitoring hospital-acquired infections to promote patient safety—United States, 1990–1999. MMWR Morb Mortal Wkly Rep. 2000;49:149–53.PubMedGoogle Scholar
  13. Fridkin  SK, Steward  CD, Edwards  JR, McGowan  JE Jr, Culver  DH, Gaynes  RP, Surveillance of antimicrobial use and antimicrobial resistance in U.S. Hospitals: Project ICARE Phase 2. Clin Infect Dis. 1999;29:245–52. DOIPubMedGoogle Scholar
  14. Garner  JS, Jarvis  WR, Emori  G, Horan  TC, Hughes  JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128–40. DOIPubMedGoogle Scholar
  15. Emori  G, Culver  DH, Horan  TC, Jarvis  WR, Olson  DR, Banerjee  S, National nosocomial infections surveillance (NNIS): Description of surveillance methods. Am J Infect Control. 1991;19:19–35. DOIPubMedGoogle Scholar
  16. Steward  CD, Wallace  D, Hubert  SK, Lawton  R, Fridkin  SK, Gaynes  RP, Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of Project ICARE laboratories. Diagn Microbiol Infect Dis. 2000;38:59–67. DOIPubMedGoogle Scholar
  17. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS approved standard M7-A5. 5th ed. Wayne (PA): National Committee for Clinical Laboratory Standards; 2000.
  18. National Nosocomial Infection Surveillance System. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Surveillance Report, data summary from January 1996 through December 1997. Am J Infect Control. 1999;27:279–84. DOIPubMedGoogle Scholar
  19. Fridkin  SK, Edwards  JR, Pryor  ER, McGowan  JE Jr, Tenover  FC, Culver  DH, Determinants of vancomycin use in adult intensive care units at U.S. hospitals. Clin Infect Dis. 1999;28:1119–25. DOIPubMedGoogle Scholar
  20. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance recommendations of the hospital infection control practices advisory committee (HICPAC). MMWR Morb Mortal Wkly Rep. 1995;44:1–13.PubMedGoogle Scholar
  21. Starr  P. The framework of health care reform. N Engl J Med. 1993;329:1666–72. DOIPubMedGoogle Scholar
  22. Epstein  AM. The outcomes movement—will it get us where we want to go? N Engl J Med. 1990;323:266–70.PubMedGoogle Scholar
  23. Lomas  J, Enkin  M, Anderson  GM, Hannah  WJ, Vayda  E, Singer  J. Opinion leaders versus audit and feedback to implement practice guidelines: delivery after previous cesarean section. JAMA. 1991;265:2202–7. DOIPubMedGoogle Scholar
  24. Everitt  DE, Soumerai  SB, Avorn  J, Klapholz  H, Wessels  M. Changing surgical antimicrobial prophlylaxis practices through education targeted at senior department leaders. Infect Control Hosp Epidemiol. 1990;11:578–83.PubMedGoogle Scholar

Main Article

Page created: April 19, 2012
Page updated: April 19, 2012
Page reviewed: April 19, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external